Scholar Rock Advances Apitegromab Toward Potential 2026 Launches

Scholar Rock Holding ( (SRRK) ) has shared an announcement.

Scholar Rock on May 7, 2026 reported first-quarter 2026 results and recent milestones, highlighting FDA acceptance of its Biologics License Application for apitegromab in spinal muscular atrophy with a Sept. 30, 2026 PDUFA action date and ongoing EMA review, while confirming preparations for potential U.S. and European launches later in 2026 supported by dual fill-finish facilities and a progressing subcutaneous formulation. The company posted a wider quarterly net loss of $105.5 million with no revenue but ended March 31, 2026 with $479.9 million in cash, cash equivalents and marketable securities after tapping $100 million in debt and raising $98 million via an ATM program, leaving it well-funded to advance its SMA franchise, initiate the mid-2026 FORGE Phase 2 trial in facioscapulohumeral muscular dystrophy, and continue development of next-generation myostatin inhibitor SRK-439.

Scholar Rock also noted the FDA’s recent reinspection of Catalent Indiana, one of its two apitegromab fill-finish sites, and expects a facility classification within 90 days, while commercial supply from its second U.S. facility is slated for early third quarter 2026, underpinning launch readiness. Enrollment continues in the Phase 2 OPAL trial in infants and toddlers with SMA and a completed Phase 1 study of subcutaneous apitegromab sets the stage for future regulatory discussions, positioning the company to strengthen its competitive standing in neuromuscular disease treatments despite rising R&D and G&A expenses.

The most recent analyst rating on (SRRK) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.

Spark’s Take on SRRK Stock

According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.

The score is held back primarily by weak financial performance (zero revenue, widening losses, and heavy cash burn) and limited valuation support due to negative earnings. Offsetting this are solid technical strength and a relatively positive earnings-call outlook driven by progressing regulatory/commercial plans and improved financing flexibility, though execution and manufacturing/regulatory risks remain material.

To see Spark’s full report on SRRK stock, click here.

More about Scholar Rock Holding

Scholar Rock Holding Corp. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for spinal muscular atrophy and other rare, severe neuromuscular diseases, leveraging its proprietary myostatin biology platform to create highly selective monoclonal antibodies that target proteins regulating muscle mass. The Cambridge, Mass.-based company’s lead candidate, apitegromab, is a first-in-class, muscle-targeted monoclonal antibody that has shown clinically meaningful benefit in a pivotal Phase 3 trial in SMA and underpins a growing pipeline, including programs in facioscapulohumeral muscular dystrophy and broader muscle disorders.

Average Trading Volume: 1,441,693

Technical Sentiment Signal: Buy

Current Market Cap: $5.41B

See more insights into SRRK stock on TipRanks’ Stock Analysis page.